Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
Jordan W ConwayRobert V RawsonSerigne N LôTasnia AhmedIsmael A VergaraTuba N GideGrace Heloise AttrillMatteo S CarlinoRobyn P M SawJohn F ThompsonAndrew J SpillaneKerwin F ShannonBrindha ShivalingamAlexander Maxwell MenziesJames S WilmottGeorgina V LongRichard A ScolyerInes Pires daSilvaPublished in: Journal for immunotherapy of cancer (2022)
Liver and brain melanoma metastases have a significantly reduced immune infiltrate than lung, subcut and LN metastases, which may account for poorer prognosis and reduced immunotherapy response rates in patients with liver or brain metastases. Increased TIM-3 expression in liver metastases suggests TIM-3 inhibitor therapy as a potential therapeutic opportunity to improve patient outcomes.